Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06875960 · ClinicalTrials.gov registry record · Phase 4

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

A Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 4
Development phase
35
Enrollment target
4
Study locations

NCT06875960 is a Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants, below the 1,062-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06875960, a Phase 4 study of Systemic Lupus Erythematosus (SLE) and Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 4
Development phase
35 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

Conditions Studied

Systemic Lupus Erythematosus (SLE) Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Interventions

  • DRUG BMS-986165

Study Locations (4)

Connecticut

  • Local Institution - 0001 - Farmington

New York

  • New York University School Of Medicine - New York

Oklahoma

  • Oklahoma Medical Research Foundation - Oklahoma City

Tennessee

  • Local Institution - 0003 - Jackson

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2026-02-27
Est. Completion 2026-12-01
Phase Phase 4

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06875960

The ClinicalTrials.gov registry entry for NCT06875960 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,062-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (97% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which BMS-986165 is the first listed.

NCT06875960 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Connecticut, New York, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT06875960 about?

NCT06875960 is a clinical study titled "A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132". The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132

What is the current status of trial NCT06875960?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2026-02-27. Estimated completion is 2026-12-01.

What conditions does trial NCT06875960 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE).

What interventions are being tested in trial NCT06875960?

The interventions under investigation include: BMS-986165 (DRUG).

Who is sponsoring clinical trial NCT06875960?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06875960 being conducted?

This trial has 4 study locations across Connecticut, New York, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus (SLE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus (SLE)

All registered trials for this condition

Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.